Isocitrate dehydrogenase (IDH) mutations produce high levels of the ‘oncometabolite’ R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain. A recent study in Nature Cancer by Friedrich et al. describes how IDH-mutant-derived R-2-HG elicits an immunosuppressive phenotype in glioma-associated macrophages. As such, the authors uncovered a new vulnerability that can be exploited for therapy.

中文翻译：

---

IDH 突变脑肿瘤用 R-2-羟基戊二酸击中巨噬细胞的阿喀琉斯之踵

异柠檬酸脱氢酶 (IDH) 突变会产生高水平的“oncometabolite”R-2-羟基戊二酸 (R-2-HG)，并在脑胶质瘤的发生和发展中起关键作用。Friedrich等人最近在Nature Cancer 上的一项研究。描述了 IDH 突变体衍生的 R-2-HG 如何在胶质瘤相关巨噬细胞中引发免疫抑制表型。因此，作者发现了一个可用于治疗的新漏洞。